Published: 31 December, 2018 | Volume 2 - Issue 1 | Pages: 013-019
Figure 7:
Changes in the dynamics of the average values of the intensity of whole blood CL in 30 patients with COPD before (2) and after (3) therapy by Hypoxen® and during acute attack (1). Hypoxen® which is the new promising antioxidant and antihypoxant that demonstrates remarkable ROS protective effect in patients with COPD and appears to have very few contradictions. Chemiluminometer "Biotoks-7a" was used.
Read Full Article HTML DOI: 10.29328/journal.jprr.1001009 Cite this Article Read Full Article PDF
HSPI: We're glad you're here. Please click "create a new Query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."